Word is this morning that Chemical and Engineering News has let at least 8 staff members go in a reorganization, including former editor-in-chief Maureen Rouhi. The magazine outsourced its advertising sales some months ago, rather than...Show More Summary
Yet another California county plans to ask the pharmaceutical industry to fund a drug take-back program.
You may recall that Sanofi basically threw its hands up in the air some time back about its entire oncology R&D efforts. Or, since they're so relentlessly French over there, perhaps it was the Gallic Shrug instead. Either one would fit - the company just wasn't seeming to get anywhere. Show More Summary
We’re excited to announce that 50 patient groups, consumer organisations and medical societies have come together to launch AllTrials USA today! These groups have said: "We are calling on everyone in our sector to join us in supporting the AllTrials campaign. Show More Summary
New research finds some serious risks are not disclosed on consent forms given to trial participants for studies involving approved drugs.
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Show More Summary
Today, I learned from a @Novartis tweet that yet another celebrity is teaming up with a pharmaceutical company to leverage "social media" for marketing purposes. The celebrity is singer and LGBT rights activist Cyndi Lauper, who admits...Show More Summary
This week sees a major update to the PLOS Collection “Blue Marble Health: the mismatch between national wealth and population health” with the addition of 50 new papers, including two new editorials published today in PLOS Medicine and PLOS Neglected … Continue reading » The post Update to Blue Marble Health Collection appeared first on Speaking of Medicine.
Pharma Delays Reporting Serious Drug AEs (i.e., Death) to FDA
Let’s review the latest edition of EvaluatePharma’s World Preview 2015, Outlook to 2020. (The document is free with site registration.) This annual report projects for prescription drug sales and R&D activity in the U.S. and abroad. Below you'll find my handy summary table comparing 2020’s best-selling U.S. Show More Summary
OK, let's stop doing this. Here's the head of the Fred Hutchinson Cancer Institute, telling people that "It is actually plausible that in 10 years we will have cures and therapies for most, if not all, human cancers". I object, on several...Show More Summary
Former Merck vaccine head Adel Mahmoud explains the reasoning for creating a global vaccine development fund.
Some Mylan shareholders claim in a lawsuit that a tax inversion the drug maker pursued to thwart hostile takeovers was predicated on a “sham” and that Mylan executives breached their fiduciary duty.
Top of the morning to you. And a steamy one, it is. In fact, there is more steam rising from the grounds of the Pharmalot campus than from our ritual cup of stimulation. But this is to be expected at this time of year, yes? In any event, there is work to be done, so as always, we have assembled a few items of interest for you. Show More Summary
The European Union has accepted a recommendation to suspend hundreds of drugs that were authorized for use based on what regulators called “flawed” studies conducted by GVK Biosciences, a clinical research organization based in Hyderabad, India.
Karin Purshouse (@karinpurshouse), a clinical and academic junior doctor in Oxford, invites you to join the conversation with other early career researchers at the next OpenCon Community Call, this Wednesday, July 29. It is not always easy, as a junior researcher, … Continue reading » The post Hello, We’re Open appeared first on Speaking of Medicine.
U.K. doctors and public health officials may be required to report any financial ties to drug makers under plans that are being considered by U.K. government officials.